Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dermatophagoides Farinae

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44 result(s) found for: Dermatophagoides Farinae. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2013-005394-45 Sponsor Protocol Number: MM09-STD-011 Start Date*: 2015-09-03
    Sponsor Name:Inmunotek, S.L.
    Full Title: Dermatophagoides pteronyssinus and Dermatophagoides farinae allergen extract. Determination of the allergenic potency in vivo histamine equivalent units (HEP)
    Medical condition: Allergy to mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004870 10020419 House dust mite allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-000870-79 Sponsor Protocol Number: 101-PG-PSC-186 Start Date*: 2012-02-17
    Sponsor Name:Laboratorios LETI, S.L.U.
    Full Title: Prospective study to evaluate the safety of a 4-month treatment with Depigoid® Dermatophagoides pteronyssinus or 50% Dermatophagoides pteronyssinus / 50% Dermatophagoides farinae (500 DPP/ml) in pa...
    Medical condition: Allergic rhinitis or rhinoconjunctivitis with or without mild persistent or intermittent asthma, to Dermatophagoides pteronyssinus or Dermatophagoides pteronyssinus and Dermatophagoides farinae.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10020419 House dust mite allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002177-62 Sponsor Protocol Number: SU-M-01 Start Date*: 2012-11-05
    Sponsor Name:ALK-Abelló A/S
    Full Title: A Dose Response Evaluation of SLIToneULTRA HDM Mix Immunotherapy
    Medical condition: Allergic rhinitis induced by house dust mites (HDM)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10038738 - Respiratory, thoracic and mediastinal disorders 10001723 Allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-003270-28 Sponsor Protocol Number: VB-02-DFLOP Start Date*: 2014-01-27
    Sponsor Name:Instituto de Inmunología y Alergia INMUNAL S.A..U.
    Full Title: Biological standardization of allergenic extracts of Dermatophagoides farinae and Lolium perenne. Open label. Single Center. Phase II Study.
    Medical condition: Biological standardization for allergenic extracts in patients with hipersensibility to extracts.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10001708 Allergic conditions HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003930-41 Sponsor Protocol Number: DME_01 Start Date*: 2007-11-20
    Sponsor Name:Curalogic A/S
    Full Title: Assessment of the Maximal Tolerated Dose of a Microencapsulated House Dust Mite (Dermatophagoides pteronyssinus and Dermatophagoides farinae) Extract (MHDME) in Subjects with House Dust Mite Allerg...
    Medical condition: Allergic rhinoconjunctivitis due to house mite dust allergy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004262-34 Sponsor Protocol Number: MM09-SIT-023 Start Date*: 2020-04-28
    Sponsor Name:Inmunotek, S.L.
    Full Title: Randomized, placebo-controlled, prospective clinical trial of efficacy and safety for the treatment of rhinitis/rhinoconjunctivitis and asthma against a mixture of Dermatophagoides pteronyssinus an...
    Medical condition: House dust mites allergy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10020419 House dust mite allergy LLT
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    21.1 100000004855 10034382 Perennial allergic rhinitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004223-46 Sponsor Protocol Number: SL75.14 Start Date*: 2015-09-16
    Sponsor Name:Stallergenes
    Full Title: A randomized, double-blind, placebo-controlled, multi-center study of the efficacy and safety of STG320 sublingual tablets of house dust mite (HDM) allergen extracts in adults and adolescents with ...
    Medical condition: House dust mite allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10001725 Allergic rhinitis due to other allergen LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed) SK (Completed) DE (Completed) CZ (Completed) BG (Completed) PL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-000487-28 Sponsor Protocol Number: VO72.12 Start Date*: 2013-08-20
    Sponsor Name:STALLERGENES SA
    Full Title: A dose ranging study investigating the efficacy and safety of sublingual immunotherapy tablets of house dust mite allergen extracts in adults with house dust mite-associated allergic asthma
    Medical condition: house dust mite-associated allergic asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004870 10020419 House dust mite allergy LLT
    14.1 100000004855 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) GB (Completed) SK (Completed) DE (Completed) CZ (Completed) BE (Completed) ES (Ongoing) PL (Completed) BG (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002017-11 Sponsor Protocol Number: AV-M-01 Start Date*: 2011-09-26
    Sponsor Name:ALK-Abelló S. A.
    Full Title: Estudio abierto para evaluar la tolerabilidad de la inmunoterapia con AVANZ Dermatophagoides mezcla
    Medical condition: Rinoconjuntivitis alérgia inducida por ácaros del polvo con o sin asma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-000820-27 Sponsor Protocol Number: MM09-SIT-013 Start Date*: 2016-02-16
    Sponsor Name:Inmunotek, S.L.
    Full Title: Double blind, placebo-controlled, dose finding, prospective, multicenter clinical trial for the treatment of rhinitis/rinoconjuntivitis against a mixture of Dermatophagoides pteronyssinus and Derma...
    Medical condition: Mites allergy
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004870 10020419 House dust mite allergy LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000446-34 Sponsor Protocol Number: MT-18 Start Date*: 2020-07-14
    Sponsor Name:ALK-Abelló A/S
    Full Title: A 28-day, single-armed, open-label trial to evaluate safety of the house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet in adolescent subjects (12-17 years of age) with HDM allergic...
    Medical condition: Allergic rhinitis/rhinoconjunctivitis induced by house dust mite
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10020419 House dust mite allergy LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2012-000672-42 Sponsor Protocol Number: BIA-STD-003 Start Date*: 2012-10-11
    Sponsor Name:Bial Industrial Farmacéutica S.A.
    Full Title: Biological standardization of allergen extracts of pollen of Artemisa vulgaris and Platanus acerifolia and the acarus Dermatophagoides farinae in patients sensitized to them.
    Medical condition: Treatment and diagnosis of allergy to Artemisa vulgaris, Platanus acerifolia and Dermatophagoides farinae.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10036019 Pollen allergy LLT
    14.1 10021428 - Immune system disorders 10066092 Acaridae allergy LLT
    14.1 10021428 - Immune system disorders 10048908 Seasonal allergy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001316-31 Sponsor Protocol Number: E01/04/SLIT1-M Start Date*: Information not available in EudraCT
    Sponsor Name:ALK-ABELLO, S.A.
    Full Title: TOLERABILIDAD DE LAS VACUNAS ALERGÉNICAS VALORADAS EN UNIDADES DE MASA Y ADMINISTRADAS POR VÍA SUBLINGUAL. ESTUDIO RANDOMIZADO DOBLE CIEGO CONTROLADO CON PLACEBO EN PACIENTES CON ENFERMEDAD ALÉRGIC...
    Medical condition: Rinitis o rinoconjuntivitis alérgica perenne (ácaros) o estacional (gramíneas) con/sin síntomas de asma
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2005-004675-37 Sponsor Protocol Number: SHX0556 Start Date*: 2006-03-16
    Sponsor Name:ALK-SCHERAX Arzneimittel GmbH
    Full Title: Multicenter, randomized, double-blind, placebo-controlled parallel group study to demonstrate the efficacy of a 12-month subcutaneous specific immunotherapy with ALK-depot SQ Milbenmischung in pati...
    Medical condition: Desensibilisierung gegenüber Allergenen
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029263 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003014-39 Sponsor Protocol Number: MM09-SIT-040 Start Date*: 2022-04-08
    Sponsor Name:Inmunotek, S.L.
    Full Title: Prospective, randomised, double-blind, double-dummy, placebo-controlled multicenter clinical trial of efficacy and safety with immunotherapy in patients with controlled mild to moderate allergic as...
    Medical condition: Etiological treatment of mild to moderate controlled intermittent or persistent allergic asthma and intermittent or persistent allergic rhinitis / rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10020419 House dust mite allergy LLT
    21.1 100000004855 10034382 Perennial allergic rhinitis LLT
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    21.1 100000004855 10001705 Allergic asthma LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-005079-21 Sponsor Protocol Number: LOTAB_2b_HDM Start Date*: 2018-08-23
    Sponsor Name:Lofarma S.p.A.
    Full Title: A Prospective, Multicenter, Double-Blind, Placebo-Controlled, Dose-Finding Phase-II Study for the Efficacy and Safety of LAIS® House Dust Mites Sublingual Tablets in Patients with Mite-Induced Alle...
    Medical condition: Patients Suffering from Mite-Induced Allergic Rhino-Conjunctivitis Without or With Controlled Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001454-77 Sponsor Protocol Number: VO57.07 Start Date*: 2007-09-12
    Sponsor Name:Stallergenes S.A
    Full Title: A randomised, double-blind, placebo-controlled, multi-national Phase II/III study of the safety and efficacy of two doses of sublingual immunotherapy (SLIT) administered as allergen-based tablets o...
    Medical condition: House dust mite allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001723 Allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) FR (Completed) DE (Completed) ES (Completed) NL (Completed) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001795-20 Sponsor Protocol Number: MT-02 Start Date*: 2006-06-29
    Sponsor Name:ALK-Abelló A/S
    Full Title: A phase II-III trial assessing the efficacy and safety of three doses of the ALK HDM tablet in house dust mite allergic subjects
    Medical condition: IgE mediated House dust mite induced mild to moderate asthma and mild to severe allergic rhinitis.
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) DK (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020079-22 Sponsor Protocol Number: DG40.08 Start Date*: Information not available in EudraCT
    Sponsor Name:STALLERGENES S.A.
    Full Title: Determination of sensitivity and specificity of five solutions of allergen extract (5 grasses, birch, ragweed pollens and Dermatophagoides pteronyssinus and Dermatophagoides farinae mites) for diag...
    Medical condition: Allergy to grass pollen Allergy to birch pollen Allergy to ragweed pollen Allergy to mites
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039085 Rhinitis allergic LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001855-38 Sponsor Protocol Number: 8237-003 Start Date*: 2012-09-03
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase IIb, Randomized, Placebo-Controlled, Dose-Finding Clinical Trial to Study the Safety and Efficacy of MK-8237 using an Environmental Exposure Chamber in Subjects with House Dust induced Alle...
    Medical condition: House Dust Induced Rhinitis/Rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001723 Allergic rhinitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 20:24:42 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA